-
Jyothy Laboratories reported a good quarter. Margins have beat estimates while EBITDA grew almost 37 percent, in fact, margins have improved despite lower gross margins and higher ad spends. In an interview to CNBC-TV18, Ullas Kamath, Joint MD of the company discussed the Q3 performance.
-
We are completely geared up for the launch of ayurvedic products, personal care products by 2021-2022, MP Ramachandran, Chairman & Managing Director of Jyothy Laboratories said.
-
In an interview to CNBC-TV18, K Ullas Kamath, Joint MD & CFO of Jyothy Laboratories spoke about the latest happenings in his company and the sector.
-
In an interview to CNBC-TV18, K Ullas Kamath, Joint MD & CFO of Jyothy Laboratories spoke about the latest happenings in his company and sector.
-
Jyothy Laboratories reported a weak set of Q1 earnings. K Ullas Kamath, Joint MD and CFO of the company spoke about the results and his outlook for the company.
-
In an interview to CNBC-TV18, K Ullas Kamath, Joint MD & CFO of Jyothy Laboratories spoke briefly about goods and services tax (GST) and the latest happenings in the company.
-
In an interview with CNBC-TV18, K Ullas Kamath, Joint MD and CFO of the company said that due to demonetisation sales in November saw a decline of 19 percent but it grew 14 percent in December and a similar trend is being seen for the month of January as well.
-
Price at which stake can be bought will be decided mutually and it cannot be less than Sebi guidelines, says K Ullas Kamath, Joint MD and CFO of Jyothy Laboratories.
-
Speaking to CNBC-TV18, Raghunandan says that rural demand will be much better in 2016.
-
S Raghunandan, whole-time director and CEO of Jyothy Laboratories says Ujala, the company‘s lead brand in the fabric whitener segment enjoys a dominant position with 78 percent market share.
-
In an interview to CNBC-TV18, K Ullas Kamath, joint managing director & chief financial officer, Jyothy Laboratories, shares his views on the company's likely performance in Q3 and the impact the Chennai floods will have on the same.
-
In an interview to CNBC-TV18, K Ullas Kamath, Joint MD & CFO of Jyothy Laboratories spoke about their second quarter numbers.
-
In an interview with CNBC-TV18, Ullas Kamath, Joint MD and CFO of Jyothy Laboratories said the rural and urban demand are improving with a fall in commodity prices and low inflation numbers.
-
The company is also aiming for a top line growth of 18-20 percent for FY15.
-
K Ullas Kamath, joint managing director and CFO of Jyothy Laboratories says the company will get the benefit of softer raw material costs in the third and fourth quarter. The company‘s expenditure rose to 12.6 percent this quarter, higher than the usual 10 percent, he adds.
-
We expect 15-20 percent EBITDA in laundry service eventually, Ullas Kamath, joint managing director of Jyothy Laboratories said.
-
FMCG player Jyothy Labs reported a 63.11 percent increase in its standalone net profit to Rs 27.37 crore for the third quarter ended December 31, 2013.
-
Speaking to CNBC-TV18, Ullas Kamath, joint managing director, Jyothy Labs says the company now has a was chest of Rs 250 crore which the pharma company will use to expand inorganically.
-
Ullas Kamath, Joint Managing Director says the company will stick to its guidance of 20-25 percent topline growth and 14-15 percent EBITDA for full fiscal year.
-
According to Ullas Kamath, the company is seeing robust volume growth in the semi urban and rural and will hold on to its guidance of 20 percent upward on the topline growth for FY14.
-
Jyothy Laboratories today posted two-fold increase in net profit to Rs 28.70 crore for the first quarter ended June 30, 2013. Ullas Kamath, Joint Managing Director of the company told CNBC-TV18 that it has given the guidance of 20-25 percent on topline and 15 percent EBITDA margins.
-
For Jyothy Labs they have a fantasttic team in place, products in place, integration too is complete and good cash flows too are coming in, therefore they are now ready to do their best, adds Ullas Kamath of Jyothy Laboratories.
-
Soaps and detergent maker Jyothy Laboratories expects its topline to rise 25 percent year-on-year in FY2014, as it expands into new geographies and products, Ullas Kamath, Joint MD, said on Friday.
-
K Ullas Kamath, deputy managing director of Jyothy Laboratories sees 25% top-line growth and 25% bottom-line growth in FY13.
-
K Ullas Kamath, deputy managing director, Jyothy Laboratories says, he expects the company to grow standalone top-line and bottom-line by 25% for the entire year.
